A Study of the Presence of Follicular T Cells in the Peripheral Blood of People with Nasal Allergies to Ragweed

Overview

About this study

The purpose of this study is to measure the presence of follicular T cells in the peripheral blood of people who have a nasal allergy response to ragweed.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria 

  • Age 18-65 years.
  • Normal healthy individuals: 
    • No history of asthma or allergic rhinitis;
    • If done previously, they should have a history of negative methacholine responsiveness (PC 20 methacholine >16 mg/ml), negative skin prick test results and/or negative IgE serum tests to 10 common aeroallergens (including house dust mite, several molds, dog, cat, trees, and grasses).
  • Patients with ragweed allergic rhinitis:
    • Moderate-to-severe allergic rhinitis (AR) to ragweed.  The clinical diagnosis of AR is established by history, where patients describe the typical seasonal symptoms, and is confirmed with a positive skin prick test and/or positive IgE serum tests to ragweed.
  • Patients will be recruited these patients from the clinical practice of the Mayo Clinic Division of Allergic Diseases, as well as from an established database of allergic rhinitis patients.  If previously done, they should have a history of a positive skin prick test and/or positive IgE serum test to ragweed within the past 5 years.  

Exclusion Criteria:

  • Received topical or systemic glucocorticoids during the past 8 weeks.
  • Previous (within the past 10 years) or current smokers.
  • Lower or upper airway infection (e.g., “common cold”) in the last 4 weeks.
  • Diagnosed with immunodeficiency or cystic fibrosis.
  • Pregnancy.                              
  • Asthma.
  • Current or past immunotherapy.
  • Perennial allergy symptoms.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Hirohito Kita, M.D.

Closed for enrollment

Contact information:

Kay Bachman R.N., C.C.R.C.

(507) 284-5689

bachman.kay@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Hirohito Kita, M.D.

Closed for enrollment

Contact information:

Temeka Simmons

(480) 301-9224

Simmons.Temeka@mayo.edu

More information

Publications

Publications are currently not available